[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anastomosis-surgical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anastomosis-surgical":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,54,81,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053425","a-post-market-real-world-experience-expanding-access-to-care-by-incorporating-the-symani-surgical-system-and-enabling-surgeons-100053425",false,"NCT06725030","A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons","PRECISE: A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons","PRECISE","Pre Operative Inclusion Criteria:\n\n1. At least 22 years of age\n2. Patient agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure\n3. Patient has a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free-flap surgery of the breast or extremities and\u002For lymphovenous anastomosis surgery of the extremities\n4. Investigator deems the candidate acceptable for free flap transfer surgery and\u002For lymphovenous anastomosis surgery with a robotic assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)\n\nCohort Specific Pre- Operative Inclusion Criteria:\n\nFree Tissue Transfer Surgery: N\u002FA\n\nLymphovenous Anastomosis Surgery\n\n1. Swelling of one limb that is not completely reversed by elevation or compression\n2. Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system\n3. At least one of the following positive quantitative measurements:\n\n   1. Volumetry differential between affected limb and contralateral limb must be at least 10% of the other\n   2. Bioimpedance (L-Dex) differential, if feasible, between affected limb and contralateral limb of at least 10 units\n4. Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines, for at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen\n5. Willingness to comply with recommended regimen of self-care, with consistent use of appropriately sized compression garments from screening through the entire study duration (through the 3-month follow-up visit).\n\nPre-Operative Exclusion Criteria:\n\n1. Patients who are incapable and\u002For unwilling to provide informed consent\n2. Active systemic infection under treatment with intravenous antibiotics\n3. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators discretion\n4. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease\n5. Patients with implanted pacemaker\n6. Planned vein graft\n7. Currently receiving chemotherapy or radiation therapy\n8. History of chronic kidney disease\n9. History of chronic liver disease\n10. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes\n11. Patients belonging to vulnerable populations, such as pregnant women, or ineligible to participate for other reasons in the judgement of the investigator\n\nCohort Specific Pre-Operative Exclusion Criteria:\n\nFree Tissue Transplant Surgery:\n\n1. Patients with buried flaps\n2. Multiple flaps planned for the procedure\n\nLymphovenous Anastomosis Surgery:\n\n1. Patients \\> 75 years of age\n2. Patients with prior lymphatic reconstruction surgery\n3. Patients with venous edema (arising from increased capillary filtration)\n4. Patients with other medical conditions that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure\n5. Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema\n6. Current infection in the affected limb\n7. Patients who experience more than one episode of cellulitis in a six month period over the past two years\n8. Current evidence or a history of malignancy within the past 6 months (if the participant has undergone cancer treatment, this must have been completed \\> 6 months prior to enrollment)\n9. Known iodine sensitivity\n10. Patient's lymphatic disease is due to lipedema\n11. Patients with bilateral lymphedema or lymphedema in multiple anatomical locations\n\nIntra Operative Exclusion Criteria:\n\n1. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest\n2. The patient does not have at least one robotic stitch attempted during the index procedure","ALL","22 Years",{"count":20,"type":21},455,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery.\n\nThe primary endpoints are:\n\n* Effectiveness- Rate of intraoperative anastomosis patency at first attempt.\n* Safety- Freedom from device-related adverse events.\n\nParticipants will receive treatment as standard of care and be asked to:\n\n* Allow the researchers to access and use their information.\n* If participants are undergoing a lymphedema procedure, they will be asked to undergo a questionnaire as part of the study.\n* Participants will be asked to comply with the follow-up visits and complete all study procedures\u002Fquestionnaires as outlined in the protocol.",[25,26,27,28,29],"Open Surgery","Lymphedema","Free Tissue Transfer","Microsurgery","Anastomosis, Surgical","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2025-09-22",{"date":38,"type":21},"2027-12-01",{"name":40,"class":41},"MMI (Medical Microinstruments, Inc.)","INDUSTRY",6,{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":46,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":50,"completionDateStruct":51,"leadSponsor":52,"locationsCount":53},"100571805",{"count":20,"type":21},[25,26,27,28,29],"2026-03-04",{"date":49,"type":34},"2026-03-05",{"date":36,"type":34},{"date":38,"type":21},{"name":40,"class":41},4,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":5},"100587450","magdi-us-registry-100587450","NCT06928545","MagDI U.S. Registry","Post-Market Assessment of the Incidence and Severity of Internal Hernia and Bowel Obstruction at One Year Following Use of the MagDI System to Create Side-to-Side Duodeno-Ileal Magnetic Compression Anastomoses (MagDI US Registry)","Inclusion Criteria:\n\n1. \\>21 years of age, at the time of informed consent.\n2. Body Mass Index (BMI) between 30-50 kg\u002Fm2.\n3. Indicated for a side-to-side duodeno-ileal anastomosis and is treated with the MagDI System at a U.S. registry center.\n4. Participant has been informed of the nature of the registry.\n\nExclusion Criteria:\n\n1\\. Participant does not provide informed consent to be enrolled and followed in the registry.",{"count":62,"type":21},106,"12 Months","Assess the incidence and severity of internal hernia and bowel obstruction at one year in a U.S. population following use of the MagDI System to create side-to-side duodeno-ileal anastomoses.",[29,66,67],"Internal Hernia","Bowel Obstruction",[69,70,71],"GT Metabolic","MagDI System","Magnetic Anastomosis","2026-02-19",{"date":74,"type":34},"2026-02-20",{"date":76,"type":34},"2025-03-28",{"date":78,"type":21},"2027-04",{"name":80,"class":41},"GT Metabolic Solutions, Inc.",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100625837","evaluation-of-musa-3-in-microsurgical-anastomoses-100625837","NCT07427823","Evaluation of MUSA-3 in Microsurgical Anastomoses","Clinical Safety and Performance Evaluation of MUSA-3 in Microsurgical Anastomoses","Inclusion Criteria:\n\n* Patient age ≥ 18 years.\n* Patients requiring procedures involving micro-anastomosis of small anatomical structures-such as blood vessels, nerves, or lymphatic vessels-in free flap, lymphatic, or peripheral nerve surgery.\n* Patients who have been selected by the research team at the Clinical Center as appropriate candidates for treatment with MUSA-3 in accordance with the IFU.\n* Able to give informed consent before participating in the study.\n* Provision of signed and dated informed consent form.\n\nExclusion Criteria:\n\n* Subject participates in a potentially confounding drug or device trial during the course of the study.\n* Patients that are pregnant or breastfeeding.\n\nFor Lymphedema patients:\n\n* ≥ISL (International Society of Lymphology) Stage III lymphedema\n* History of marcaine or indocyanine green allergy\n* Non-viable lymphatic system as determined by ICG lymphatic mapping using near infrared camera","18 Years",{"count":90,"type":21},30,"INTERVENTIONAL",[93],"NA","This study is conducted to evaluate the safety and performance of robot-assisted microsurgical anastomoses with the MUSA-3 system.",[29],"NOT_YET_RECRUITING","2026-02-16",{"date":99,"type":34},"2026-02-23",{"date":101,"type":21},"2026-04-20",{"date":103,"type":21},"2026-09-28",{"name":105,"class":41},"Microsure",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":113,"targetDuration":115,"studyType":22,"phases":4,"briefSummary":116,"conditions":117,"keywords":124,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100570559","augur-ai---indocyanine-green-fluorescence-angiography-representer-100570559","NCT06708819","AUGUR-AI - Indocyanine Green Fluorescence Angiography Representer","AUGUR-AI","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Aged 18 years or above.\n* Colorectal disease requiring segmental resection with anastomosis.\n* Participant has clinically acceptable laboratory results, including liver function tests.\n* In the Investigator's opinion, is able and willing to comply with all study requirements.\n* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n\nExclusion Criteria:\n\nThe participant may not enter the study if ANY of the following apply:\n\n* Participant who is pregnant, lactating or planning pregnancy during the course of the study.\n* Significant renal or hepatic impairment.\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Allergy to intravenous contrast agent or indocyanine green.\n* Concurrent use of anticonvulsants, bisulphite containing drugs, methadone and nitrofurantoin.",{"count":114,"type":21},300,"90 Days","Surgery can effectively treat colorectal cancer, but it is a complex procedure with risks and complications. Surgeons often rely on cameras to visually guide their instruments during operations, especially in minimally invasive (\"keyhole\") and endoscopic procedures. The camera is connected to a computer and generates the internal scene onto a display screen, which the surgeon looks at throughout the procedure, helping them make informed decisions throughout the operation. Fluorescence-guided surgery uses a particular type of camera that can detect images in both normal light and in the near-infrared range. To work, it needs the administration of an agent called indocyanine green to a patient and then the camera can see if the agent is in the tissue of interest to the operation at the time of the surgery. In this way, decisions regarding blood supply (\"perfusion\") can be helped, especially related to safety in joining together portions of tissue after removal of disease. The equipment and agent are approved for use in this way and have very good safety profiles. Many international studies have already demonstrated that the use of fluorescence-guided surgery is associated with lower rates of leaks when disease bowel segments are removed, and the healthy ends are joined back together.\n\nPrevious work we have done has shown that sophisticated computing methods can learn to interpret the fluorescence patterns to a similar standard as a surgeon who is very experienced in fluorescence-guided surgery.\n\nIn this study, we aim to assess whether the computer system we have developed work in real-time, in theatre to provide a reliable interpretation of the fluorescence pattern, that would match how an expert would interpret the same pattern. The system's analysis will not impact on the operation; instead, video images will be recorded, processed and analysed by our computer system. The results of the interpretation will not be shown to the operating surgeon during the procedure to avoid any impact on decision-making.",[118,119,29,120,121,122,123],"Colorectal Surgery","Colorectal Resection","Fluorescence Guided Surgery","Indocyanine Green","Perfusion Imaging","Anastomotic Leaks",[125,121,126,127,128],"Fluorescence","Artificial Intelligence","Bowel Transection","Anastomotic Leak","2024-11-26",{"date":131,"type":34},"2024-11-27",{"date":133,"type":21},"2025-01",{"date":135,"type":21},"2026-01",{"name":137,"class":138},"Mater Misericordiae University Hospital","OTHER",1]